Integrated or Standalone? How the Industry Thinks About Drug Development Outsourcing

By Syngene International

Outsourcing integrated drug development programmes is potentially a highly effective and efficient way to advance therapeutics. Putting one contract development and manufacturing organisation (CDMO) in charge of all tasks can enable the seamless progress of programmes and ensure a hassle-free outsourcing experience. However, anecdotal evidence of occasional failures points to the need to have a well-defined strategy.

To gain insight into perceptions of differing outsourcing strategies, Syngene and Pharma Intelligence surveyed industry leaders about their experiences. This free white paper analyses the results of the survey.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.